Oncopeptides AB (STO:ONCO), a Swedish biotech company focused on difficult-to-treat cancers, said on Wednesday that it has formed a strategic partnership with SD Pharma, a Spanish pharmaceutical broker specialising in oncology and haematology, to expand the commercial reach of its multiple myeloma treatment, Pepaxti, across hospital networks in Spain.

The collaboration is designed to enhance physician engagement beyond Oncopeptides' current focus areas by leveraging SD Pharma's expertise in oncology and haematology distribution.

SD Pharma will deploy Medical Science Liaisons for clinical education and Regional Access Managers to manage treatment access and logistics.

Established in 2013, SD Pharma has a proven track record in launching pharmaceutical and medical device products and maintains partnerships with companies including BCG, Recordati, Laboratorios Leadiant, Chiesi, and Airways Medical Devices.

The partnership will operate on a success-based model, with no upfront or fixed costs for Oncopeptides.

Operational rollout is expected to begin in the third quarter of 2025.

Pepaxti, also known as melphalan flufenamide, holds marketing authorisation in the European Union, the EEA countries, and the UK for relapsed or refractory multiple myeloma patients meeting specific treatment history criteria.